Skip to main content
Premium Trial:

Request an Annual Quote

DNAVision to Offer Ipsogen's MapQuant Breast Cancer Test

NEW YORK (GenomeWeb News) – DNAVision said yesterday that it will offer Ipsogen’s new MapQuant Dx Genomic Grade test through its central lab services in Europe.
 
The MapQuant Dx is a molecular diagnostic, gene expression-based test that measures tumor grade, risk of metastasis, and chemotherapy response, among breast cancer patients. Ipsogen launched the test last week.
 
The MapQuant runs on Affymetrix’s GeneChip platform and was developed under an agreement between Affy and Marseille, France-based Ipsogen in August 2007.
 

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.